These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Management of prostate cancer. Part 3: metastatic disease. Shah J; Khaksar SJ; Sooriakumaran P Expert Rev Anticancer Ther; 2006 May; 6(5):813-21. PubMed ID: 16759171 [TBL] [Abstract][Full Text] [Related]
25. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Rahman KM; Banerjee S; Ali S; Ahmad A; Wang Z; Kong D; Sakr WA Cancer Res; 2009 May; 69(10):4468-75. PubMed ID: 19435906 [TBL] [Abstract][Full Text] [Related]
26. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. Sava T; Basso U; Porcaro A; Cetto GL Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438 [TBL] [Abstract][Full Text] [Related]
27. Angiogenesis as a strategic target for prostate cancer therapy. Li Y; Cozzi PJ Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866 [TBL] [Abstract][Full Text] [Related]
29. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer. Shabbir M; Ryten M; Thompson C; Mikhailidis D; Burnstock G BJU Int; 2008 Feb; 101(3):352-9. PubMed ID: 18005209 [TBL] [Abstract][Full Text] [Related]
30. Prostate cancer: horizons in the development of novel anti-cancer strategies. Papatsoris AG; Papavassiliou AG Curr Med Chem Anticancer Agents; 2001 May; 1(1):47-70. PubMed ID: 12678770 [TBL] [Abstract][Full Text] [Related]
31. Future therapies in hormone-refractory prostate cancer. Smith MR; Nelson JB Urology; 2005 May; 65(5 Suppl):9-16; discussion 17. PubMed ID: 15885273 [TBL] [Abstract][Full Text] [Related]
32. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life? Cella D; Petrylak DP; Fishman M; Teigland C; Young J; Mulani P Eur Urol; 2006 May; 49(5):781-9. PubMed ID: 16458417 [TBL] [Abstract][Full Text] [Related]
33. [Targeted therapies for hormone-refractory prostate cancer]. Song HZ; Chen LB Zhonghua Nan Ke Xue; 2010 Dec; 16(12):1108-12. PubMed ID: 21348204 [TBL] [Abstract][Full Text] [Related]
34. [Therapy of hormone refractory prostate cancer: new standards, new trends]. Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408 [TBL] [Abstract][Full Text] [Related]
35. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Miyoshi Y; Ishiguro H; Uemura H; Fujinami K; Miyamoto H; Miyoshi Y; Kitamura H; Kubota Y Prostate; 2003 Sep; 56(4):280-6. PubMed ID: 12858356 [TBL] [Abstract][Full Text] [Related]
36. New approaches in hormone refractory prostate cancer. Sonpavde G; Hutson TE Am J Clin Oncol; 2006 Apr; 29(2):196-201. PubMed ID: 16601442 [TBL] [Abstract][Full Text] [Related]
37. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Yoshino T; Shiina H; Urakami S; Kikuno N; Yoneda T; Shigeno K; Igawa M Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6116-24. PubMed ID: 17062688 [TBL] [Abstract][Full Text] [Related]
38. Targeting the relaxin hormonal pathway in prostate cancer. Neschadim A; Summerlee AJ; Silvertown JD Int J Cancer; 2015 Nov; 137(10):2287-95. PubMed ID: 25043063 [TBL] [Abstract][Full Text] [Related]
39. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005? Strother JM; Beer TM; Dreicer R Eur J Cancer; 2005 Apr; 41(6):954-64. PubMed ID: 15808961 [TBL] [Abstract][Full Text] [Related]
40. Cell signaling modifiers in prostate cancer. Chen FL; Armstrong AJ; George DJ Cancer J; 2008; 14(1):40-5. PubMed ID: 18303482 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]